Flupentixol
Based on 2 publication(s) in Google Scholar
Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2709-56-0
- Fòrmula: C23H25F3N2OS
- Peso molecular:434.52
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Flupentixol
MoreVer todos los productos específicos de isoformas Dopamine Receptor
More
Actividad biológica
|
D1 Receptor |
D2 Receptor |
PI3Kα 127 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Astrocyte | EC50 |
1.182 μM
Compound: 7
|
Antiproliferative activity against mouse astrocyte cells by MTT assay
Antiproliferative activity against mouse astrocyte cells by MTT assay
|
[PMID: 17417631] |
| HEK293 | IC50 |
89.5 μM
Compound: flupenthixol
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
|
[PMID: 18788725] |
| Medulloblastoma cell | EC50 |
0.187 μM
Compound: 7
|
Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
|
[PMID: 17417631] |
Flupentixol (2.5-40 μM; 72 h) treatment inhibits the viability of lung cancer cells in a dose-dependent manner[3].
Flupentixol (2.5-40 μM; 24 h) induces apoptosis in lung cancer cells[3].
Flupentixol (2.5-15 μM; 24 h) inhibits p-AKT and Bcl-2 expression levels[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, H661, SK-SEM-1, and NCAL-H520 cells
-
Concentration:2.5, 5, 10, 20, or 40 μM
-
Incubation Time:72 hours
-
Result:Showed the IC50s of 5.708 μM and 6.374 μM for A549 and H661 cells, respectively.
-
Cell Line:A549 and H661 cells
-
Concentration:5, 10, 20 and 40 μM
-
Incubation Time:24 hours
-
Result:Increased the percentage of cells in early apoptosis compared with the negative control in both A549 and H661 (p< 0.05). Induced the cleavage of PARP and caspase-3 in a dose-dependent manner.
-
Cell Line:H661 and A549 cells
-
Concentration:2.5, 5, 10, and 15 μM
-
Incubation Time:24 hours
-
Result:Decreased AKT phosphorylation levels in a dose-dependent manner, decreased the expression levels of Bcl-2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C nude mice injected with A549 cells[3]
-
Dosage:40 mg/kg
-
Administration:Intragastric injection; 40 mg/kg; once daily; 21 days
-
Result:Reduced tumor volumes compared to the vehicle control (p<0.05), reduced tumor weights by 64.1% (p<0.05).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 2709-56-0
-
Peso molecular 434.52
-
Fòrmula C23H25F3N2OS
-
SMILES
OCCN1CCN(CC/C=C2C3=C(SC4=C/2C=CC=C4)C=CC(C(F)(F)F)=C3)CC1
-
Synonyms
Flupenthixol
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Insect Biochem Mol Biol
Molecular and pharmacological characterization of the dopamine receptors in the oriental fruit fly, Bactrocera dorsalis. [Abstract]2025 May:180:104312. PMID: 40245998
Pureza y Documentación
Referencias
[1]. Yonar D, et al. Effect of cis-(Z)-flupentixol on DPPC membranes in the presence and absence of cholesterol. Chem Phys Lipids. 2016 Jun;198:61-71. [Content Brief]
[2]. Ruhrmann S, et al. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1012-22. [Content Brief]
[3]. Chao Dong, et al. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer. Int J Biol Sci. 2019 Jun 2;15(7):1523-1532. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)